tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Apogee Therapeutics price target raised to $95 from $90 at Wedbush
PremiumThe FlyApogee Therapeutics price target raised to $95 from $90 at Wedbush
18d ago
Apogee Therapeutics Stock: Clinical-Stage Risks, Unproven Pipeline, and Uncertain Path to Profitability
Premium
Company Announcements
Apogee Therapeutics Stock: Clinical-Stage Risks, Unproven Pipeline, and Uncertain Path to Profitability
18d ago
Apogee Therapeutics reports FY25 net loss $255.8M vs. $182.1M last year
Premium
The Fly
Apogee Therapeutics reports FY25 net loss $255.8M vs. $182.1M last year
19d ago
Mizuho biotech analysts hold an analyst/industry conference call
PremiumThe FlyMizuho biotech analysts hold an analyst/industry conference call
2M ago
Apogee Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
Premium
The Fly
Apogee Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
2M ago
Wayfair upgraded, Instacart initiated: Wall Street’s top analyst calls
Premium
The Fly
Wayfair upgraded, Instacart initiated: Wall Street’s top analyst calls
2M ago
Apogee Therapeutics price target raised to $84 from $81 at BofA
PremiumThe FlyApogee Therapeutics price target raised to $84 from $81 at BofA
2M ago
Apogee Therapeutics: Upgraded Outlook on Zumilokibart’s Superior Asthma Data, Dual-Label Potential, and Strengthened Buy Thesis
Premium
Ratings
Apogee Therapeutics: Upgraded Outlook on Zumilokibart’s Superior Asthma Data, Dual-Label Potential, and Strengthened Buy Thesis
2M ago
Apogee Therapeutics price target raised to $137 from $128 at BTIG
Premium
The Fly
Apogee Therapeutics price target raised to $137 from $128 at BTIG
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100